A Phase I Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Bortezomib; Dasatinib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 06 Jul 2012 Actual patient number changed from 14 to 16 as reported by ClinicalTrials.gov record.
- 06 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 14 Jun 2010 Planned end date changed from 1 Jun 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.